Rhinocerebral mucormycosis (zygomycosis) primarily affects diabetic or immunosuppressed patients and typically progresses rapidly, necessitating surgical excision and antifungal therapy with amphotericin B. Large doses of amphotericin B are required for cure, causing significant renal toxicity. Amphotericin B colloidal dispersion (ABCD; Amphocil, Sequus Pharmaceuticals, Menlo Park, CA) is a 1:1 complex of cholesteryl sulfate and amphotericin B, which results in significant reduction of toxicity, especially nephrotoxicity. We describe three patients with life-threatening rhinocerebral mucormycosis treated with ABCD. All patients had high serum creatinine levels due to prior treatment with amphotericin B; these levels reverted to normal during treatment with ABCD. Two patients with diabetes mellitus were cured after receiving a combination of surgery and ABCD therapy. The third patient, who had myelodysplastic syndrome, had an initial good response, with cure of the fungal infection; however, he eventually died of his primary illness. To the best of our knowledge, this is the first detailed clinical description of the treatment of mucormycosis with ABCD.
Mucormycosis (zygomycosis) is a life-threatening infection
infection [2] . It is postulated that the chelating agent acts as a siderophore that enhances fungal growth. caused by molds belonging to the order Mucorales of the class Since its introduction four decades ago, amphotericin B has Zygomycetes. Members of this order are found in decaying been the mainstay of therapy for invasive fungal disease [3] . vegetables, seeds and fruits, compost piles, animal excreta, soil,
The usual dosage is 1.0 -1.5 mg/(kgrd). Some of the fungi, and stale bread. Members of the genera Rhizopus, Rhizomucor, especially molds, are susceptible only to higher doses of amAbsidia, and Mucor are the main etiologic agents of mucorphotericin B, as can be demonstrated by MICs of ú6 mg/mL mycosis and have a wide geographic distribution [1] . Mucorfor R. oryzae. Amphotericin B exerts its antifungal effects by mycosis is usually encountered as a secondary disease or an binding to ergosterol, which is present in the cell membranes opportunistic infection in immunocompromised hosts, most of of susceptible fungi. This binding results in a change in permewhom have underlying conditions such as diabetic ketoacidosis ability of the fungal cell membrane, allowing leakage of a or major trauma [2] .
variety of small molecules. An additional mechanism of action, The route of infection is either through inhalation of the at least in vitro, may include oxidative damage to fungal cells. spores or via abraded skin. Typically, in tissue the fungal hyBecause of the renal toxicity associated with amphotericin B phae invade blood vessels, which progressively leads to thromtherapy, there has been interest in finding new formulations of bosis followed by necrosis with the development of a black the drug that would be less toxic but no less efficacious. The eschar that is the clinical hallmark of these infections. The development of amphotericin B that is administered in associaclinical presentation may be specific to the host. Rhinocerebral tion with a lipid moiety, such as a lipid colloidal dispersion mucormycosis caused by Rhizopus oryzae is seen most often of liposomal amphotericin B or lipid complex, rather than in in diabetics, and pulmonary infection is more common in paassociation with bile salts, has made it possible to prescribe tients with neutropenia secondary to chemotherapy for hematofar higher dosages of amphotericin B with fewer subsequent logic malignancies [2] . Patients with ocular involvement may side effects. present with proptosis, chemosis, and paralysis of extraocular Amphotericin B colloidal dispersion (ABCD; Amphocil, muscles. It has recently been shown that treatment with the Sequus Pharmaceuticals, Menlo Park, CA) is a novel assembly chelating agent deferoxamine poses a risk for acquiring the that combines amphotericin B and cholesteryl sulfate in a 1:1 molar ratio to form a lipid delivery system [4] . ABCD particles are a disk-like array, with diameters ranging from 120 nm to 140 nm. The formulation is dispensed in lyophilized form and
Case Reports
Case 1. A 44-year-old woman was admitted to another hospital for evaluation of left facial pain. Her medical history was significant for hypertension, alcohol abuse, and an 8-year history of non -insulin-dependent diabetes mellitus. Three days before admission she had complained of severe pain and swelling of her left cheek and forehead in association with visual disturbances. A diagnosis of diabetic ketoacidosis and invasive infection of the ethmoid and maxillary sinuses was made. Left ethmoidectomy and turbinectomy were performed. Broad (7 -15 mm in diameter) nonseptate hyphae that branched at 90Њ angles, compatible with a zygomycete, were seen within the blood vessels and in pathological sections of the surrounding ance of periocular swelling. A CT scan disclosed spread of an invasive process of the sinus into the left orbit, penetrating the bone, and a cerebral abscess of the left frontal lobe. Extensive sinus debridement and left orbital enucleation were performed.
branched at a 90Њ angle, characteristic of mucormycosis. ConOver the next 2 days the patient's renal function deteriorated, sequently, she was transferred to our hospital for further treatand her serum creatinine level increased to 230 mmol/L (normal ment. A CT scan disclosed an infiltrating lesion of the ethmoid, range, 44 -97 mmol/L); therefore, she was transferred to our maxillary, and sphenoid sinuses, with involvement of the base hospital. Shortly after admission, massive debridement of the of skull. Extensive surgery with extirpation of the soft and hard left maxillary and ethmoid sinuses was performed, and more palate was performed by surgeons from the department of oral soft tissue was removed from the left eye. The brain abscess and maxillofacial surgery in collaboration with staff from the was drained under stereotactic guidance, and a culture yielded department of otolaryngology. The patient concurrently started Pseudomonas aeruginosa that was susceptible only to imireceiving amphotericin B at a dosage of 1 mg/(kgrd). Within penem and gentamicin.
4 weeks she developed moderate renal failure, with a serum Pathological examination of the aspirated material disclosed creatinine level of 170 mmol/L. Therapy was changed to that wide-angle, branching, broad nonseptate hyphae, consistent with ABCD. The dose was gradually increased to 4 mg/(kgrd), with mucormycosis, although no fungi were recovered in with complete resolution of the renal failure (figure 1). culture. Treatment with ABCD, administered at a dosage of Over the next 4 weeks, the patient's course was complicated 5 mg/(kgrd), together with imipenem and gentamicin, was by line sepsis due to P. aeruginosa, from which she recovered. started. Dexamethasone therapy was initiated for brain edema.
After 3 months of therapy with ABCD, she was discharged to Over the next 2 months the patient's condition improved a day care center. Because of the initial involvement of the slowly, but repeated superficial debridement of her sinuses was base of skull, which could not be debrided, treatment with needed. The fungal infection remained under control, and her ABCD was continued for an additional 3 months, three times renal function returned to normal. She was discharged to reper week at 4 mg/kg per dose. Thus, she received a total of ceive amphotericin B, 1 mg/kg, once every other day.
30 g of ABCD. The treatment was then changed to that with The patient received a 2-month course of therapy with imiamphotericin B, 1 mg/(kgrd), once a week. Repeated MRI penem, until complete resolution of the abscess cavity was scans disclosed no new lesions. noted on a CT scan. An ocular prosthesis was placed in the After 8 months, a permanent oral prosthesis was prepared left eye socket. She then continued to receive amphotericin B for the patient. She gradually regained weight and resumed twice a week for 2 more months. Thus, the total amount of normal activities. After a total of 18 months of weekly therapy ABCD administered was 12.3 g over a period of 8 weeks, with amphotericin B, the treatment was stopped. Repeated MRI with an additional 2 g of amphotericin B. Three years after scans were obtained initially after 1 month and then every 3 -completion of therapy, there is no evidence of recurrent fungal 6 months for 1 1 / 2 years, and no new findings were observed. disease.
Two and one-half years after cessation of all therapy, the patient Case 2. A 72-year-old woman with insulin-dependent diaremains well. betes mellitus was admitted to another hospital for treatment Case 3. A 62-year-old man was admitted to another hospiof a necrotic oropharyngeal lesion. Biopsy of the soft palate tal for evaluation of periorbital pain and swelling of 3 days' duration. His medical history was remarkable for myelodysrevealed necrotic tissue invaded by nonseptate hyphae that / 9c4e$$ju22 05-19-98 12:53:56 cida UC: CID plastic syndrome of 6 months' duration. He was known to be incidence of disseminated candidiasis. Several years after the introduction of empirical therapy with amphotericin B, there a carrier of hepatitis B surface antigen and had anti-hepatitis C antibodies and abnormal liver function. After receiving treathas been an increase in the number of infections with relatively resistant fungi such as species of Fusarium and Aspergillus and ment with steroids, he developed diabetes mellitus. Mucormycosis was diagnosed on the basis of histological findings in members of the Zygomycetes. Eradication of these infections necessitates high-dose, long-term therapy with amphotericin B, sections from his maxillary sinus, and cultures of the biopsy specimens yielded Rhizopus species. Because of severe hemorwith more frequent adverse effects. Rhinocerebral mucormycosis is often a rapidly progressive rhagic diathesis, an attempt to completely debride the involved area was aborted, and he was transferred to our hospital.
infection that may be fatal in a short period. This infection is most often seen in diabetics or immunocompromised hosts. On admission the peripheral WBC count was 4,200/mm 3 , the hemoglobin level was 8.2 g/dL, and the platelet count was Early, extensive surgical debridement of the focus of infection, combined with antifungal therapy, provides the only prospect 60,000/mm 3 . The serum creatinine level was 270 mmol/L. A CT scan showed soft-tissue swelling in the left maxillary sinus for cure. For the three patients described herein, an aggressive surgical approach was combined with high-dose amphotericin area where the operation had been performed. There was a suspected destructive bony lesion of the ethmoid sinuses on B therapy. All three patients started receiving ABCD because of renal failure, which occurred in two days after treatment the left. All the sinuses showed increased tissue density. Therapy with high-dose ABCD (the dosage rapidly reached with amphotericin B was initiated. Renal function reverted to normal in all three patients despite treatment with £6 mg/ 6 mg/[kgrd]) was started. After initial improvement in the patient's condition, which lasted for several days, the swelling (kgrd) of ABCD. The total quantity of ABCD that was administered ranged worsened. Single donor platelets were prepared, and the patient underwent debridement of the left maxillary sinus and ethmoibetween 10 g and 32 g. The duration of ABCD administration ranged between 6 weeks and 6 months and was followed by dosphenoidostomy. After the operation, the facial swelling almost completely resolved. The diplopia and pain disappeared. treatment with low-dose amphotericin B for prolonged periods. The patient in case 2 had involvement of the base of skull While receiving ABCD at a dosage of 6.0 mg/(kgrd), the patient developed nausea and vomiting and lost his appetite.
that could not be completely debrided, and the infection was unquestionably cured with ABCD, since she remains healthy His liver function deteriorated: the alanine aminotransferase level rose to 251 U/L (normal level, 53 U/L), the aspartate ú2 years after cessation of therapy. Studies in mice, rats, and dogs have shown that ABCD is aminotransferase level rose to 269 U/L (normal level, 40 U/L), and the g-glutamyltranspeptidase level rose to safer than amphotericin B. The LD 50 of ABCD in mice has been shown to be ú10 mg/kg, compared with 0.6 -0.8 mg/kg 273 U/L (normal level, 80 U/L). Reduction of the dosage of ABCD to 4.5 mg/(kgrd) led to an immediate improvement in for amphotericin B [7] . In these studies in mice, organ distribution was compared between the different formulations of amhis liver function. After 42 days of therapy, he was discharged to receive amphotericin B twice a week at home. At this stage photericin B. The concentration of amphotericin B delivered by ABCD in the liver was 12 times that delivered by amphoteria CT scan still showed a soft-tissue density filling the nose and nasopharynx and extending into the left sphenoidal sinus with cin B; in the spleen, it was four times that delivered by amphotericin B; and in kidneys and plasma, it was less than that interruption of its floor and anterior wall. Complete debridement was never attempted because of the patient's tendency delivered by amphotericin B. The concentration in normal brain tissue is usually low but was slightly higher with amphotericin toward severe bleeding.
After 8 weeks of treatment with amphotericin B at home, the B than with ABCD. In contrast, concentrations of ABCD in infected brain tissue were slightly higher than those of amphomucormycosis flared up but rapidly responded to an increase in the dosage of a commercial liposomal amphotericin B preparatericin B.
The experience in the treatment of deep mycotic infections tion that was given for 10 weeks. After 1 year during which the patient remained symptom free, he died of a complication with lipid formulations of amphotericin B has been growing since the introduction of these formulations in 1985 [8] . Ten of myelodysplastic syndrome, without any evidence of mucormycosis.
patients with invasive fungal infection, including aspergillosis (four patients), deep candidiasis (four), and zygomycosis (two), have recently been described [9] . Liposomal amphotericin B Discussion therapy was associated with little nephrotoxicity in these patients. The overall survival rate was 50%. Of the two patients The incidence of invasive fungal infections has risen in the last several years [5, 6] . This increase is due to the availability with mucormycosis, the one with rhinosinusal zygomycosis survived, and the one with surgical wound zygomycosis died. of more-aggressive chemotherapeutic protocols and to the use of broad-spectrum antibiotics. The empirical use of amphoteriLim et al.
[10] described a 71-year-old diabetic with rhinocerebral mucormycosis who was treated with surgical debridement cin B for treatment of fever in neutropenic patients has become common practice in the past 10 years because of the increasing and liposomal amphotericin B. The patient underwent surgical / 9c4e$$ju22 05-19-98 12:53:56 cida UC: CID intervention 4 weeks after beginning therapy; however, despite dose ABCD, combined with appropriate surgical excision, is both safe and efficacious in producing long-term cure for invasurgical removal of necrotic tissue and treatment with liposomal amphotericin, this patient died 2 days after surgery.
sive mucormycosis in patients whose underlying disease can also be controlled. A chronic variety of rhinocerebral mucormycosis has occasionally been observed [11] . In one such case, in which the patient presented with a 3-month course of gradual deteriora-
